Skip to content
Participate in our active studiesSubscribe to our Mailing List
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
AB ScienceAB Science
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • Masitinib in oncology
    • Masitinib in viral diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
      • Severe Asthma
      • Prostate Cancer
      • Pancreatic Cancer
      • COVID-19
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Board of Directors Charter
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact
  • French
  • English
Search:
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • Masitinib in oncology
    • Masitinib in viral diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
      • Severe Asthma
      • Prostate Cancer
      • Pancreatic Cancer
      • COVID-19
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Board of Directors Charter
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact

Outstanding shares and voting rights

You are here:
  1. Home
  2. Investors
  3. Regulated information
  4. Outstanding shares and voting rights
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • Monthly disclosure of total outstanding shares and voting rights
    Dated January 6, 2025
  • Monthly disclosure of total outstanding shares and voting rights
    Dated October 15, 2024
  • Monthly disclosure of total outstanding shares and voting rights
    Dated September 26, 2024
  • Monthly disclosure of total outstanding shares and voting rights
    Dated July 12, 2024
  • Monthly disclosure of total outstanding shares and voting rights
    Dated June 10, 2024
  • Monthly disclosure of total outstanding shares and voting rights
    Dated April 8, 2024
  • Monthly disclosure of total outstanding shares and voting rights
    Dated February 6, 2024
  • Monthly disclosure of total outstanding shares and voting rights
    Dated January 10, 2023
  • Monthly disclosure of total outstanding shares and voting rights
    Dated December 8, 2023
  • Monthly disclosure of total outstanding shares and voting rights
    Dated November 7, 2023
  • Monthly disclosure of total outstanding shares and voting rights
    Dated October 10, 2023
  • Monthly disclosure of total outstanding shares and voting rights
    Dated August 2, 2023
  • Monthly disclosure of total outstanding shares and voting rights
    Dated July 11, 2023
  • Monthly disclosure of total outstanding shares and voting rights
    Dated June 7, 2023
  • Monthly disclosure of total outstanding shares and voting rights
    Dated April 6, 2023
  • Monthly disclosure of total outstanding shares and voting rights
    Dated March 6, 2023
  • Monthly disclosure of total outstanding shares and voting rights
    Dated February 7, 2023
  • Monthly disclosure of total outstanding shares and voting rights
    Dated January 5, 2023
  • Monthly disclosure of total outstanding shares and voting rights
    Dated December 6, 2022
  • Monthly disclosure of total outstanding shares and voting rights
    Dated October 6, 2022
  • Monthly disclosure of total outstanding shares and voting rights
    Dated September 7, 2022
  • Monthly disclosure of total outstanding shares and voting rights
    Dated May 4, 2022
  • Monthly disclosure of total outstanding shares and voting rights
    Dated April 8, 2022
  • Monthly disclosure of total outstanding shares and voting rights
    Dated March 7, 2022
  • Monthly disclosure of total outstanding shares and voting rights
    Dated February 7, 2022
  • Monthly disclosure of total outstanding shares and voting rights
    Dated January 7, 2022
  • Monthly disclosure of total outstanding shares and voting rights
    Dated December 7, 2021
  • Monthly disclosure of total outstanding shares and voting rights
    Dated October 8, 2021
  • Monthly disclosure of total outstanding shares and voting rights
    Dated September 8, 2021
  • Monthly disclosure of total outstanding shares and voting rights
    Dated August 3, 2021
  • Monthly disclosure of total outstanding shares and voting rights
    Dated July 7, 2021
  • Monthly disclosure of total outstanding shares and voting rights
    Dated June 8, 2021
  • Monthly disclosure of total outstanding shares and voting rights
    Dated May 7, 2021
  • Monthly disclosure of total outstanding shares and voting rights
    Dated March 8, 2021
  • Monthly disclosure of total outstanding shares and voting rights
    Dated March 5, 2021
  • Monthly disclosure of total outstanding shares and voting rights
    Dated February 5, 2021
  • Monthly disclosure of total outstanding shares and voting rights
    Dated January 8, 2021
  • Monthly disclosure of total outstanding shares and voting rights
    Dated December 3, 2020
  • Monthly disclosure of total outstanding shares and voting rights
    Dated November 5, 2020
  • Monthly disclosure of total outstanding shares and voting rights
    Dated September 30, 2020

  • Monthly disclosure of total outstanding shares and voting rights
    Dated September 4, 2020

  • Monthly disclosure of total outstanding shares and voting rights
    Dated August 4, 2020

  • Monthly disclosure of total outstanding shares and voting rights
    Dated July 6, 2020

  • Monthly disclosure of total outstanding shares and voting rights
    Dated June 3, 2020

  • Monthly disclosure of total outstanding shares and voting rights
    Dated May 6, 2020

  • Monthly disclosure of total outstanding shares and voting rights
    Dated April 2, 2020

  • Monthly disclosure of total outstanding shares and voting rights
    Dated March 4, 2020

  • Monthly disclosure of total outstanding shares and voting rights
    Dated February 5, 2020

  • Monthly disclosure of total outstanding shares and voting rights
    Dated January 8, 2020

  • Monthly disclosure of total outstanding shares and voting rights

    Dated December 2, 2019
  • Monthly disclosure of total outstanding shares and voting rights

    Dated November 5, 2019
  • Monthly disclosure of total outstanding shares and voting rights

    Dated October 2, 2019
  • Monthly disclosure of total outstanding shares and voting rights

    Dated September 3, 2019
  • Monthly disclosure of total outstanding shares and voting rights

    Dated August 1, 2019
  • Monthly disclosure of total outstanding shares and voting rights

    Dated June 4, 2019
  • Monthly disclosure of total outstanding shares and voting rights

    Dated May 3, 2019
  • Monthly disclosure of total outstanding shares and voting rights

    Dated April 5, 2019
  • Monthly disclosure of total outstanding shares and voting rights

    Dated January 7, 2019
  • Monthly disclosure of total outstanding shares and voting rights

    Dated December 6, 2018
  • Monthly disclosure of total outstanding shares and voting rights

    Dated November 6, 2018
  • Monthly disclosure of total outstanding shares and voting rights

    Dated October 3, 2018
  • Monthly disclosure of total outstanding shares and voting rights

    Dated September 5, 2018
  • Monthly disclosure of total outstanding shares and voting rights

    Dated July 3, 2018
  • Monthly disclosure of total outstanding shares and voting rights

    Dated June 4, 2018
  • Monthly disclosure of total outstanding shares and voting rights

    Dated May 3, 2018
  • Monthly disclosure of total outstanding shares and voting rights

    Dated April 4, 2018
  • Monthly disclosure of total outstanding shares and voting rights

    Dated March 1, 2018
  • Monthly disclosure of total outstanding shares and voting rights

    Dated February 5, 2018
  • Monthly disclosure of total outstanding shares and voting rights

    Dated January 8, 2018
  • Monthly disclosure of total outstanding shares and voting rights

    Dated December 4, 2017
  • Monthly disclosure of total outstanding shares and voting rights

    Dated November 7, 2017
  • Monthly disclosure of total outstanding shares and voting rights

    Dated October 2, 2017
  • Monthly disclosure of total outstanding shares and voting rights

    Dated August 7, 2017
  • Monthly disclosure of total outstanding shares and voting rights

    Dated July 10, 2017
  • Monthly disclosure of total outstanding shares and voting rights

    Dated June 7, 2017
  • Monthly disclosure of total outstanding shares and voting rights

    Dated May 3, 2017
  • Monthly disclosure of total outstanding shares and voting rights

    Dated April 4, 2017
  • Monthly disclosure of total outstanding shares and voting rights

    Dated March 3, 2017
  • Monthly disclosure of total outstanding shares and voting rights

    Dated February 6, 2017
  • Monthly disclosure of total outstanding shares and voting rights

    Dated January 13, 2017
Previous tab Next tab

AB SCIENCE
HEADQUARTER

3, Avenue George V – 75008 PARIS – FRANCE
Tel. : +33 (0)1 47 20 00 14
Fax. : +33 (0)1 47 20 24 11

GENERAL INQUIRIES

contact@ab-science.com

PRODUCT INQUIRIES

masivet@ab-science.com

JOB INQUIRIES

careers@ab-science.com

CLINICAL INQUIRIES

clinical@ab-science.com

MEDIA / FINANCIAL INQUIRIES

investors@ab-science.com

PHARMACOVIGILANCE

pharmacovigilance@ab-science.com
Fax : +33 1 47 20 10 82

AB Science
© AB Science – All right reserved
Go to Top